TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03769454
Drug: PP-001
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP-001 eye drops
Study: NCT02224040
Drug: ceftriaxone and azithromycin
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224040
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02224040
Drug: azithromycin and cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01142726
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, oral, 2.5 mg, once weekly, 12 months
Study: NCT01004510
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
Study: NCT00382083
Drug: 1000 mg acetaminophen
Normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00382083
Drug: 800 mg ibuprofen
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02818686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002531
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01142726
Drug: Methotrexate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Study: NCT02125981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taking placebo drug
Study: NCT00002531
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002531
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002531
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002531
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002531
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03354611
Drug: Contrast Dye, Iodinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement.
Study: NCT04079101
Drug: BIIB104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04079101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT01751854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo alone or with training
Study: NCT00243347
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02495168
Drug: Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation, brand-name product.
Study: NCT02495168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation, no active ingredient.
Study: NCT00133952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00464763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04613167
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The third group will receive only optimal guidelines-based secondary preventive treatment. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery, intima media thickness of carotid arteries and pulse wave will be measured.
Study: NCT03146533
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
Study: NCT02665286
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg PO BID x 7 days
Study: NCT02665286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
Study: NCT02940444
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01206803
Drug: Ovarian stimulation in a GnRH-antagonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
Study: NCT04695041
Drug: PBI-4050/ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive either 800mg PBI-4050 capsules or placebo, twice a day for 14 days
Study: NCT04695041
Drug: PBI-4050/ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive either 1000 mg PBI-4050 capsules or placebo, twice a day for 14 days
Study: NCT04695041
Drug: PBI-4050/ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive either 1200 mg PBI-4050 capsules or placebo, twice a day for 14 days
Study: NCT04695041
Drug: PBI-4050/ Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive either 800 mg PBI-4050 capsules or placebo, three times a day for 14 days
Study: NCT02814019
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00308906
Drug: aminoglycoside
Normalized name: Aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
Study: NCT02305134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02770690
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply normal saline before propofol iv injection
Study: NCT02411136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
Study: NCT00848354
Drug: Phase 1: Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
Study: NCT00848354
Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128.
Study: NCT00848354
Drug: Phase 1: Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
Study: NCT00848354
Drug: Phase 1: Conventiaonal DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
Study: NCT06365398
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
Study: NCT02604940
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
Study: NCT04643691
Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg and Spironolactone 25 mg pillules oral use during 10 days
Study: NCT00660660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02645253
Drug: AZD7594 inhalation powder (200 μg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
Study: NCT02645253
Drug: AZD7594 inhalation powder (400 μg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
Study: NCT02645253
Drug: AZD7594 pressurized inhalation suspension (200 μg)
Normalized name: penicillin G Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
Study: NCT02645253
Drug: AZD7594 placebo inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7594 placebo inhalation powder via multi-dose DPI
Study: NCT06365398
Drug: Heparin Sodium Injection
Normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
Study: NCT00486187
Drug: metformin or sulfonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04365387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
Study: NCT02853604
Drug: ADXS11-001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02853604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04161898
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be administered as oral tablet
Study: NCT00975494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03434275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once Daily
Study: NCT02039492
Drug: Treatment with aldactone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, single dose via intravenous infusion over 1 hour.
Study: NCT01539538
Drug: Sufentanil NanoTab PCA System/15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
Study: NCT01654484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Solution, QD, 28 days
Study: NCT02045667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets do not contain any active medicinal component.
Study: NCT01260805
Drug: Reference Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Study: NCT01260805
Drug: Test Drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Study: NCT00081653
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 3 years
Study: NCT00081653
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg po monthly for 3 years
Study: NCT03548194
Drug: BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 300 mg b.i.d
Study: NCT03548194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo b.i.d.
Study: NCT02179294
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dedicated intravenous cannula for remifentanil administration PCA protocol~* PCA bolus remifentanil 40 μg~* Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes.
Study: NCT03222960
Drug: propolis-containing toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will use propolis-containing toothpaste for 6 months
Study: NCT03222960
Drug: Fluoride-containing toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will use Fluoride-containing toothpaste for 6 months
Study: NCT00868660
Drug: ZP1848
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc. bolus
Study: NCT02741687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
Study: NCT02241629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of levo phencynonate hydrochloride
Study: NCT04464629
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Prednisolone acetate 1% ophthalmic suspension
Study: NCT00134082
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg/day on Day -3, -2, -1, and 0.
Study: NCT02279563
Drug: Dymista™ Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02279563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01592240
Drug: 300mg PF-04950615 (RN316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04950615 300 mg, Q28d
Study: NCT04492280
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
Study: NCT02042183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg soft capsules of placebo for oral administration
Study: NCT02256189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet daily
Study: NCT00378378
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: One spray of placebo nasal spray in each nostril once daily for 4 months.
Study: NCT00003955
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02454491
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraradial administration of heparin 5000 ui
Study: NCT01746745
Drug: [^14C]-LY2940680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as solution by mouth
Study: NCT03711903
Drug: Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
Study: NCT00802139
Drug: venoferrum(iron sucrose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
Study: NCT03183076
Drug: Pharmacotherapy without diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
Study: NCT00601458
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
Study: NCT00601458
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Study: NCT00729651
Drug: Comparator: Alendronate sodium (Fosamax)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate sodium; tablet, once weekly, for 16 weeks
Study: NCT03129100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01145066
Drug: borage/echium oil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
Study: NCT01774968
Drug: Human Regular U-500 Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01648101
Drug: Retigabine 900mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
Study: NCT01648101
Drug: Retigabine 600mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
Study: NCT04474405
Drug: Florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370 MBq (10 mCi), single dose
Study: NCT03636932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
Study: NCT03889639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Film coated tablet; Route of administration: Oral
Study: NCT03889639
Drug: Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Study: NCT03491410
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is to be added in the standard patient´s treatment
Study: NCT01535222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available NaCl
Study: NCT00569569
Drug: juxtascleral depot injection of Retaane
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: juxtascleral depot injection of Retaane
Study: NCT02269358
Drug: METHOTREXATE
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
Study: NCT01806298
Drug: Saizen® solution for injection (referred as Saizen®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
Study: NCT01599234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
Study: NCT00754819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily
Study: NCT01442155
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to the Summary of Product Characteristics.